Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07220772 | A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults | PHASE3 | RECRUITING | 4 | — | — | Feb 9, 2026 | Apr 21, 2028 | Mar 10, 2026 | 1 | Germany |
| Arm | Type | Description |
|---|---|---|
| Mibavademab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Mibavademab | DRUG | Administered as per the protocol |
Key Inclusion Criteria: 1. Has documented medical history of biallelic loss of function variants of the LEP gene prior to the screening visit 2. Has class ≥2 obesity at screening and at baseline, as defined in the protocol Key Exclusion Criteria: 1. Unwilling or unable to provide, or have the tre...